Stockreport

NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

NuCana plc - American Depositary Shares  (NCNA) 
Last nucana plc - american depositary shares earnings: 3/10 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/ncna/historical
PDF Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin NuTide:121 Trials-in-Progress Poster Present [Read more]